Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorSanvisens, Arantza
dc.contributor.authorRivas, Inmaculada
dc.contributor.authorFaure, Eva
dc.contributor.authorEspinach Garcia, Nestor
dc.contributor.authorHernandez-Rubio, Anna
dc.contributor.authorMajó-Roca, Xavier
dc.contributor.authorColom-Farran, Joan
dc.contributor.authorMuga, Robert
dc.date.accessioned2022-02-07T12:12:03Z
dc.date.available2022-02-07T12:12:03Z
dc.date.issued2020-10-14
dc.identifier.citationSanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio, A, Majó X, et al. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol. 2020 Oct 14;26(38):5874-5883.
dc.identifier.issn1007-9327
dc.identifier.urihttp://hdl.handle.net/11351/6983
dc.descriptionDirect-acting antiviral agents; Opioid Treatment Program; Opioid agonist therapy; Hepatitis C virus infection; Human immunodeficiency virus infection; Drug use
dc.description.abstractBackground: Direct-acting antivirals (DAAs) are recommended for the treatment of hepatitis C virus (HCV) infection in patients treated with methadone or buprenorphine. Aim: To assess HCV treatment rates in an Opioid Treatment Program (OTP). Methods: This longitudinal study included 501 patients (81.4% men, median age: 45 years; interquartile range: 39-50 years) enrolled in an OTP between October 2015 and September 2017. Patients were followed until September 2019. Data on socio-demographics, substance use, HCV infection, human immunodeficiency virus (HIV) infection and laboratory parameters were collected at entry. We analyzed medical records to evaluate HCV treatment. Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors. Results: Prevalence of HCV and HIV infection was 70% and 34%, respectively. Among anti-HCV-positive (n = 336) patients, 47.2%, 41.3%, and 31.9% used alcohol, cannabis, and cocaine, respectively. HCV-RNA tests were positive in 233 (69.3%) patients. Twentyeight patients (8.3%) cleared the infection, and 59/308 (19.1%) had received interferon-based treatment regimens before 2015. Among 249 patients eligible, 111 (44.6%) received DAAs. Treatment rates significantly increased over time from 7.8/100 person-years (p-y) (95%CI: 5.0-12.3) in 2015 to 18.9/100 p-y (95%CI: 11.7-30.3) in 2019. In a multivariate analysis, patients with HIV co-infection were twice as likely to receive DAAs (HR = 1.94, 95%CI: 1.21-3.12) than patients with HCV mono-infection. Current drug use was an independent risk factor for not receiving treatment against infection (HR = 0.48, 95%CI: 0.29-0.80). Conclusion: HCV treatment is evolving in patients with HCV-HIV co-infection. Ongoing drug use while in an OTP might negatively impact the readiness to treat infection.
dc.language.isoeng
dc.publisherBaishideng Publishing Group
dc.relation.ispartofseriesWorld journal of gastroenterology;26(38)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectInfeccions per VIH - Tractament
dc.subjectVirus de l'hepatitis C - Tractament
dc.subjectOpiacis - Ús terapèutic
dc.subject.meshHIV Infections
dc.subject.meshOpiate Substitution Treatment
dc.subject.meshHepatitis C
dc.titleMonitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3748/wjg.v26.i38.5874
dc.subject.decsinfecciones por VIH
dc.subject.decstratamiento de sustitución de opiaceos
dc.subject.decshepatitis C
dc.relation.publishversionhttp://dx.doi.org/10.3748/wjg.v26.i38.5874
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Sanvisens A] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Rivas I, Faure E, Espinach N] Mental Health and Addiction Service, Badalona Serveis Assistencials-BSA, Badalona, Spain. [Hernandez-Rubio A, Muga R] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. [Majó X, Colom J] Programa de Prevenció, Control i Atenció al VIH, les MTS i les Hepatitis Víriques, Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain
dc.identifier.pmid33132641
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record